Combined hepatocellular-cholangiocarcinoma:An update on epidemiology,classification,diagnosis and management

作     者：Dimitrios Schizas Aikaterini Mastoraki Eleni Routsi Michail Papapanou Dimitrios Tsapralis Pantelis Vassiliu Konstantinos Toutouzas Evangelos Felekouras Dimitrios Schizas;Aikaterini Mastoraki;Eleni Routsi;Michail Papapanou;Dimitrios Tsapralis;Pantelis Vassiliu;Konstantinos Toutouzas;Evangelos Felekouras

作者机构：First Department of SurgeryNational and Kapodistrian University of AthensLaikon General HospitalAthensGreece Fourth Department of SurgeryNational and Kapodistrian University of AthensAttikon University HospitalAthensGreece Surgical DepartmentGeneral Hospital of IerapetraIerapetraGreece First Department of Propaedeutic SurgeryNational and Kapodistrian University of AthensHippocration HospitalAthensGreece 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2020年第19卷第6期

页      面：515-523页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Combined hepatocellular-cholangiocarcinoma Classification Diagnostic approach Therapeutic management 

摘      要：Background:Combined hepatocellular-cholangiocarcinoma(CHC)is a rare subtype of primary hepatic malignancies,with variably reported incidence between 0.4%–14.2%of primary liver cancer *** study aimed to systematically review the epidemiological,clinicopathological,diagnostic and therapeutic data for this rare *** sources:We reviewed the literature of diagnostic approach of CHC with special reference to its clinical,molecular and histopathological *** analysis of the recent literature in order to evaluate the results of surgical and systemic treatment of this entity has been ***:The median age at CHC’s diagnosis appears to be between 50 and 75 *** of tumor markers[alpha fetoprotein(AFP),carbohydrate antigen 19–9(CA19–9)and carcinoembryonic antigen(CEA)]along with imaging patterns provides better opportunities for CHC’s preoperative *** clinicopathologic prognostic parameters possibly correlated with increased tumor recurrence and grimmer survival odds include advanced age,tumor size,nodal and distal metastases,vascular and regional organ invasion,multifocality,decreased capsule formation,stem-cell features verification and increased GGT as well as CA19–9 and CEA *** case of inoperable or recurrent disease,combinations of cholangiocarcinoma-directed systemic agents display superior results over ***-directed methods,such as transarterial chemoembolization(TACE),percutaneous ethanol injection(PEI),hepatic arterial infusion chemotherapy(HAIC),radioembolization and ablative therapies,demonstrate inferior efficacy than in cases of hepatocellular carcinoma(HCC)due to CHC’s common ***:CHC demonstrates an overlapping clinical and biological pattern between its malignant *** history of the disease seems to be determined by the predominant tumor *** standard for diagnosis is histology of surgical *** therapeutic int